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Abstract: Cartilage is frequently damaged with a limited capacity for repair. Current treatment
strategies are insufficient as they form fibrocartilage as opposed to hyaline cartilage, and do not
prevent the progression of degenerative changes. There is increasing interest in the use of autologous
mesenchymal stem cells (MSC) for tissue regeneration. MSCs that are used to treat articular cartilage
defects must not only present a robust cartilaginous production capacity, but they also must not
cause morbidity at the harvest site. In addition, they should be easy to isolate from the tissue and
expand in culture without terminal differentiation. The source of MSCs is one of the most important
factors that may affect treatment. The infrapatellar fat pad (IPFP) acts as an important reservoir for
MSC and is located in the anterior compartment of the knee joint in the extra-synovial area. The IPFP
is a rich source of MSCs, and in this review, we discuss studies that demonstrate that these cells have
shown many advantages over other tissues in terms of ease of isolation, expansion, and chondrogenic
differentiation. Future studies in articular cartilage repair strategies and suitable extraction as well as
cell culture methods will extend the therapeutical application of IPFP-derived MSCs into additional
orthopedic fields, such as osteoarthritis. This review provides the latest research concerning the use
of IPFP-derived MSCs in the treatment of articular cartilage damage, providing critical information
for the field to grow.
Keywords: infrapatellar fat pad; mesenchymal stem cells; adipose tissue; osteoarthritis; articular cartilage
1. Introduction
1.1. Articular Cartilage
Articular cartilage is a specialized connective tissue that lacks blood vessels, nerves,
and lymphatic tissue. Consequently, cartilage tissue has limited capacity for repair and the
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progression of focal cartilage defects leads to more generalized degenerative changes or
osteoarthritis [1]. Articular cartilage damage is a disabling disease characterized by fibril-
lation and subsequent destruction of the articular cartilage surface, frequently including
subchondral bone damage inducing more generalized changes [2]. The adjoining synovium
in articular cartilage disease includes biomarkers for significant inflammation, including
Substance P, which further stimulates a local inflammatory response [3,4]. Consequently,
oedema and inflammation of the infrapatellar fat pad (IPFP) and the synovial membrane
cause the progression of osteoarthritis as well as articular cartilage loss that often necessi-
tates full joint replacement. Furthermore, the synovial membrane and IPFP may interact
with each other, affecting the development and progression of osteoarthritis [4,5].
1.2. Past and Current Articular Cartilage Treatments
Cartilage defects cause a significant disease burden and a previous study indicated
that more than of 60% of knees undergoing arthroscopy have articular defects [6]. If these
defects are left untreated, or managed suboptimally, they lead to the progression of more
widespread degenerative changes. There are several methods for treating articular cartilage
defects depending on the anatomical location, extent, shape, and depth of the cartilage
defect, and age of the patient [7] (Table 1). The operative treatment techniques mentioned
in Table 1 result in the formation of the less desirable fibrocartilage, or hyaline-like cartilage,
as opposed to hyaline cartilage. Fibrocartilage has suboptimal biomechanical properties
and does not prevent the progression of the degenerative changes of osteoarthritis [8].
Studies on cell-based techniques, including Autologous Chondrocyte Implantation (ACI)
and Matrix-Assisted ACI (MACI), have highlighted the disadvantages of using fully
differentiated chondrocytes, such as their difficulty in extraction, isolation, expansion,
and growth in vivo after implantation. It is of the highest importance to find alternative
cell sources.
Table 1. Non-operative and operative treatment techniques for articular cartilage defects.
Technique Effect Reference
Non-operative Methods
Pharmacotherapy drugs (steroidal and non-steroid
anti-inflammatory drugs, glucosamine, chondroitin sulphates,
etc.) to control symptoms
[9]
Abrasion Arthroplasty Creation of a rough surface in the damaged area in order toform fibrocartilage (subchondral bone is not directly accessed) [10]
Arthroscopic Debridement Removal of the damaged part of the tissue, allowing thesubchondral bone to initiate the healing process [11]
Autologous Chondrocyte Implantation
(ACI)
Transplantation of isolated and expanded chondrocytes from
healthy cartilage to the defected area [12]
Chondroplasty Utilizes laser or radiofrequency-based probes to smooth thedamaged edges of cartilage [13]
Matrix-assisted ACI (MACI) Isolated and expanded autologous chondrocytes are combinedwith a scaffold which is implanted into the defect site [14]
Microfracture (subchondral drilling)
Subchondral bone is stimulated by drilling, allowing the bone
marrow MSCs to migrate to the damaged area and form
fibrocartilage
[15]
Mosaicplasty Osteochondral autografts or allografts are transferred from adonor site to the defect site [16]
1.3. Cell-Based Therapies
Recent advances in developing therapeutic strategies for treating articular cartilage
defects [17,18] have focused on stem cell therapies and tissue regeneration to prevent the
progression to osteoarthritis [19]. Stem cells have shown superiority in treating articular
cartilage defects due to their ease of isolation, expansion, and culture in preliminary
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studies, and are a promising method for promoting articular cartilage regeneration [20].
Mesenchymal stem cells (MSCs), in contrast to autologous chondrocytes, possess a greater
capacity to expand in vitro [19]. The use of MSCs does not raise ethical concerns, as is the
case with embryonic stem cells. Many questions need to be answered before stem cells
are routinely used for cartilage defects, including the optimal stem cell source, an optimal
extraction, isolation, and expansion protocol, the need for scaffolds, and cost. Although
adipose tissue-derived MSCs have a lower chondrogenic capacity in comparison with
bone marrow mesenchymal stem cells [21], they can be harvested in a less invasive and
cost-effective manner with liposuction. Due to this easier access, the therapeutic application
of adipose tissue-derived MSCs is increasing [22]. For all of the above reasons, the IPFP
has become an area of high interest in regenerative medicine since it stores MSC.
Despite the promise of the IPFP as a source of MSC for regenerating articular cartilage,
very few reviews exist on this subject. In this review, for the first time, the authors detail
several IPFP cell-based therapies, their current progress towards healing articular cartilage
damage, and the most recent advances in the use of IPFP-derived MSCs for cartilage repair.
2. Advantages of Adipose Tissue-Derived MSCs for Articular Cartilage Repair
The presence of MSCs in adipose tissue from liposuction was first reported in 2001
by Zuck et al. [23]. Adipose tissue-derived MSCs have also demonstrated a greater ability
to differentiate into other lineages in pre-clinical studies compared to umbilical cord stem
cells [2,24]. Adipose tissue is one of the most easily accessible tissues for the extraction
of MSCs and is often discarded after liposuction. Since increased BMI and adipose tissue
content are related to articular cartilage damage, removal of adipose tissue through lipo-
suction and subsequent isolation of adipose tissue-derived MSCs can be well suited for
treating articular cartilage damage [25,26].
Due to the potentially wide applications of MSCs in regenerative medicine, it is es-
sential to have access to a reliable and reproducible MSC source. Adipose tissue-derived
MSCs are feasible and promising candidates for cell-based therapies [27], and they can
be differentiated into adipose tissue, bone, cartilage, and muscle [28,29]. Studies have
confirmed chondrogenic differentiation of human adipose tissue-derived MSC pellet cul-
tures by the expression of target tissue markers [30]. After harvesting of adipose tissue
using liposuction aspiration or needle biopsy, adipose tissue-derived MSCs were isolated
from adipose tissue. The tissue was washed with phosphate-buffered saline and a peni-
cillin/streptomycin solution before being minced. To further dissolve any adipose tissue
clumps or aggregates, the adipose tissue was pipetted up and down numerous times to
facilitate mechanical disruption of the extracellular matrix. The tissue was then placed in a
plate of sterile tissue culture dishes and 0.05% of a collagenase digestion buffer for tissue
digestion after the debris was removed. The supernatant was aspirated after collagenase
inactivation with K-NAC medium supplemented and 10% fetal calf serum (FCS), and the
cell pellet was resuspended in a K-NAC medium supplemented with 10% FCS. Following
centrifugation, the cell suspension was blended and filtered using a 100-µm cell strainer.
Lastly, cell pellets were plated onto a tissue culture plate and cultured in an incubator at
37 ◦C with 5% CO2 [22]. Such processes are now commonly used for ADSC isolation and
can be used for articular cartilage repair.
Over the last two decades, stem cell-based therapies using adipose tissue-derived
MSCs have been expanding, as supported by their strong therapeutic potential. Studies
have reported that the effect of stem cells derived from different tissues differ according to
the site of extraction [31]. Adipose tissue is easier to access than other tissues and obtaining
MSCs from this tissue is less invasive [32]. Compared to bone marrow, the process of
harvesting tissue from adipose tissue is less invasive, and studies suggest a greater cell
yield per unit of tissue as well [33]. Studies suggest that adipose tissue-derived MSCs have
a smaller cell body than bone marrow-derived MSCs and have different gene expression
and cell surface receptors. Commonly used markers include CD90, CD44, CD29, CD105,
CD13, CD34, CD73, CD166, CD10, CD49e, and CD59, which are all positive, while CD31,
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CD45, CD14, CD11b, CD19, CD56, and CD146 are all negative in adipose tissue-derived
MSCs. In addition, the positive expression of HLA-ABC and STRO-1 as well as the negative
expression of HLA-DR are also features of adipose tissue-derived MSCs [34]. ADSCs can
all be passaged in vitro up to passage 10 with no karyotype abnormalities detected [35].
Unlike bone marrow-derived MSCs, the number, viability, and proliferation capacity of
ADSCs do not appear to be related to patient age.
Despite the important advantage of adipose tissue-derived MSCs in that they are
easier to harvest and isolate, and their increased ability to proliferate and differentiate
into chondrocytes, an incomplete understanding of the processes and mechanisms of
their differentiation have limited their clinical applications [24]. Studies have reported
important differences between various MSC sources, and this has implications on the
choice of cells for articular cartilage regeneration [36,37]. MSCs from various tissues vary
in their proliferation and differentiation properties (Table 2). An important challenge with
adipose tissue-derived MSCs is the creation of fibrous and hypertrophic cartilage instead
of articular hyaline cartilage [36].







Ease of Harvest and Isolation +++ + ++
Amounts of Tissue Obtained +++ ++ +
Capacity for Proliferation and Colony
Formation ++ + +++
Maintenance of Function Irrespective of
Donor Age ++ + +++
Suitability for Soft Tissue Regeneration
(e.g., skin, cartilage, etc.) +++ ++ +
Suitability for Hard Tissue Re-generation
(e.g., bone, tooth, etc.) + ++ +++
+ weak, ++ moderate, +++ strong.
3. IPFP-Derived MSCs Used in Cartilage Repair
IPFP-derived MSCs are a subset of MSCs and may have higher cartilage regeneration
potential than other MSCs due to their proximity to the knee joint and similarity to subcuta-
neous adipose tissue cells; they are also more easily accessible than other MSC tissues [39].
The IPFP is intracapsular and extra-synovial, and is located between the patellar tendon,
the femoral condyle, and the tibial plateau [40]. The IPFP is a less invasive source of
MSCs that can be easily accessed with less morbidity arthroscopically [40]. Obtaining
subcutaneous fat by liposuction can obtain a large amount of adipose tissue, however, this
can be associated with complications such as skin necrosis, scarring, hematoma, allergic
reactions to drugs, temporary bruising, numbness, and nerve injury [41,42].
The cellular environment and adjacent tissues alter cell gene expression [43]. The
IPFP is adjacent to the synovial membrane and the synovial fluid as well as articular
cartilage, and is potentially influenced by this anatomical location in terms of stem cell
differentiation [44]. Additionally, the IPFP cells are likely to be positively affected by
biomolecules in the synovial membrane and synovial fluid including TGF-β1, vitamin
C, and FGF [43]. Studies show that cartilage-derived morphogenic protein-1 (CDMP-1)
and osteogenic protein-1 (OP-1) are more highly expressed in the synovial tissue than in
articular cartilage tissue [33], and this can certainly affect IPFP-derived MSC numbers,
differentiation, and function [45,46].
The general characteristics of IPFP and adipose tissue-derived MSCs are similar,
but the differentiation capacity of IPFP-derived MSCs compared to a chondrogenic and
osteogenic lineage is higher than that of adipose tissue-derived cells. SOX-9, collagen
type II, and aggrecan gene expression are higher in IPFP-derived MSCs than adipose
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tissue-derived MSCs, which may explain their more optimal use for articular cartilage
regeneration applications [47].
IPFP, and specifically the macrophages from the tissue, can be candidates for the
future treatment of cartilage defects and chondrogenesis [42]. Importantly, polarization of
macrophages to pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes led to an
upsurge in TGF-β (a pro-chondrogenic and anti-inflammatory cytokine) that may play a
key role in the differentiation of MSCs and subsequent cartilage repair.
In summary, the use of IPFP-derived MSCs to regenerate articular cartilage has led to
encouraging results. The collaboration of researchers from many disciplines and different
fields will help address current challenges concerning the therapeutic role of IPFP-derived
MSCs, including the best isolation process, and should pave the way for the improved
treatment of articular cartilage. Future detailed studies regarding articular cartilage repair
strategies focusing on suitable material and methods may eventually extend the application
of IPFP-derived MSCs to a future therapeutic role in osteoarthritis.
Many MSCs when injected into the body migrate away from damaged tissue to healthy
tissue and a suitable carrier may be needed to “anchor” the MSCs in place [48]. The identifica-
tion of the optimal cell source as well as the optimal carrier material for these cells plays an
important role in the success of stem cell-based regenerative strategies (Table 3).
Table 3. Some important studies on IPFP-derived MSCs for articular cartilage repair that use a carrier.
Cell Source Carrier Outcome Reference
Porcine IPFP-derived MSCs Agarose hydrogels
Chondrogenic differentiation of cells in vitro
were shown by histochemistry and biochemical
analyses of glycosaminoglycans, as well as







In vitro chondrogenesis of cells promoted for 21
days, as demonstrated by histochemistry and
biochemical analyses of glycosaminoglycans
[50]
Human IPFP-derived MSCs 3D-printed chitosanscaffolds
Cartilage-like tissue formed on the constructs
after 4 weeks of culture, as demonstrated by
immunohistochemistry analyses and collagen
type II, aggrecan, and SOX9 gene expression
[51]
Human IPFP-derived MSCs Acellular dermal matrix(ADM) from rat dermis
Differentiation towards a hyaline-like cartilage
phenotype on the constructs as proven by the
expression of collagen type II, aggrecan, and






Constructs promoted hyaline-like cartilage
formation in vivo, evaluated by SOX9 and
aggrecan expression for over 6 months
[53]
IPFP-derived MSCs Scaffold-free 3D pelletculture
Constructs provided osteochondral regeneration
in a rat osteochondral defect model within 12
weeks
[54]
Human IPFP-derived MSCs Scaffold-free 3D pelletculture
Constructs integrated well into the femoral
condyle, presenting hyaline cartilage features as
indicated by SOX9 and COL2A1 gene expression
in vitro and in vivo
[55]
Rabbit IPFP-derived MSCs 3D gelatin-basedbiomimetic scaffold
Chondrogenic tissue formation as evidenced by
collagen type II, aggrecan, and SOX9 expression
in vitro for 3 weeks
[56]
The studies mentioned above and other important studies in the literature that used
IPFP-derived MSCs for regenerative applications in chondrogenesis are listed in Table 4.
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Table 4. Studies on IPFP-derived MSC proliferation and chondrogenic differentiation.
Tissue Donor Assay Results References
Articular Cartilage in the Knee in a Porcine
Model (n = 3) (4 months old)
Cells harvested and
population doubling time
FGF-2 increased IPFP-derived MSC
proliferation [57]
Pigsty (n = 2) (5 months old) Cell calculation
ECM development promoted
IPFP-derived MSC proliferation and
maintained stem cell morphology
[58]
Patients for Sectional Surgical Removal of a
Meniscus





Transforming growth factor beta (TFP)
completion considerably promoted the
proliferation rate of the meniscus of joint
cells, IPFP-derived MSC, and SDSCs, but
less than that of adipose tissue-derived
MSCs
[59]
Adolescent Patients with Anterior Cruciate
Ligament (ACL) Trauma for Regeneration
(n = 4) (17.2 (SD 0.7)
years old)
Cell calculation
IPFP-derived MSC has less proliferative
capacity than SDSCs but more than
ScASCs
[60]
Osteoarthritis in Old Patients for Whole
Knee Arthroplasty (n = 4) (70.5 (SD 9.2)
years old)
Cell counting
IPFP-derived MSC have more
proliferative capacity compared with
SDSCs but more than other cases
[61]
IPFP-derived MSCs from Sheep Knees (n =
5) (10,12,14,16,18 months old)
Transplantation of
IPFP-ASCs
Hyaline cartilage-like formed in some
cartilage defects [62]
IPFP-derived MSCs from Sheep Knees (n =
5) (12
months old)
Assay of doubling time
ASC
Maintain proliferation potential and
fibroblastic-like morphology of
IPFP-derived MSCs during different
passages
[53,62]
IPFP-derived MSCs Patients (n = 7) (74
years old)
Isolation of IPFP-stem
cells and cell calculation
The extracellular matrix fragments in
suspension prevented the calculation of
cells
[63]
IPFP, Patients (n = 5) (50 years old)
Yielding of IPFP by
liposuction and isolation
of stem cells
IPFP-derived MSCs are an important




Patients (n= 8 Men and 17 Women) (30
years old)
Assaying the stem cell
injection
IPFP-derived MSCs treatment with
intra-articular injections is effective and
reduces pain
[45]
Macrophages from Adipose tissue, Patients
with Osteoarthritis (60 years old)
Harvesting of
macrophages from IPFP
The macrophages from IPFP can change
articular cartilage-based stem cell therapy [65]
4. Clinical Applications of IPFP-Derived MSCs for Articular Cartilage Repair
From a therapeutic perspective, clinical studies have already been conducted using
adipose tissue and IPFP-derived MSCs (Table 5) [66]. In a clinical study, an average of
1.89 × 106 MSCs isolated from osteoarthritic knees were combined with 3 mL of platelet-
rich plasma and placed in a novel biological scaffold. Twenty five patients (eight men and
seventeen women) with knee osteoarthritis received these percutaneously administered
injections combined with arthroscopic debridement [45,66]. The constructs, along with
platelet-rich plasma, were transplanted into articular cartilage defects to facilitate articular
cartilage repair. This study showed that at a one-year follow-up, patient knee pain grading
scores, including the Tegner activity scale, the mean Lysholm, and visual analog scale
(VAS), all significantly improved, with 92% of 25 patients showing an improvement in
these scores.
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Table 5. Clinical studies on the use of MSCs for articular cartilage regeneration.
Study Cases Outcome Prospects Reference
Autologous adipose
tissue-derived MSCs






Osteonecrosis of the hip
femoral head: 1 female
(age 29) and 1 male (age
47)
Osteoarthritis: 2 females
(ages 70 and 79)
Bone formation in osteonecrosis
patients and cartilage formation in
osteoarthritis patients within 1–3
months, as evidenced by MRI











male and 17 female
patients (age range,
34–69)
Pain reduction and improvement in
function in patients with knee
osteoarthritis within 3–18 months
For knee osteoarthritis,
this could be an
effective treatment after
optimization of some














resulting in pain reduction and
improvement in function 6 months
after the injection into osteoarthritic
knees
Large randomized




The use of IPFP-derived MSCs in such clinical studies led our group to use adipose-
derived MSCs with polycaprolactone to form a 3D “cartilage-like” chondrogenic structure
which was then transplanted into small cartilage defects in the knees of sheep. Tissue was
isolated from the IPFP of five male sheep and after 6 months, amorphous proliferative
tissue was regenerated in the defect area. Real time RT-PCR analysis proved collagen
protein expression as well as greater cartilage regeneration compared to controls [69,70].
In this study, the ideal size of a cartilage defect was designated as 1 mm in depth and
4 mm in diameter. A 3D IPFP-derived MSC/polycaprolactone structure was directly
transplanted into the defects. Within 6 months, the 3D graft improved cartilage formation
and regenerated the cartilage without any inflammatory reaction and in the newly formed
cartilage tissue, polygonal chondrocyte clusters were shown. As a result, histological
analysis, including staining of safranin O, morphological assays, and the expression of type
I and type II collagen, confirmed hyaline-like cartilage formation but without integration
into the surrounding cartilage [68].
One of the most prominent clinical studies to date [68] described the safety and effects
of an intra-articular injection of adipose tissue-derived MSCs prepared from abdominal
subcutaneous fat obtained by liposuction [71] on 18 patients with knee osteoarthritis. At
the final six-month follow-up, results demonstrated the formation of new cartilage in the
knee joint at the medial femoral and tibial condyles, and a decrease in cartilage defect size
using Magnetic Resonance Imaging (MRI).
Dufrane et al. used human adipose tissue-derived MSCs with a demineralized bone
matrix to generate a 3D, bone-like construction and transplanted them into large bone
defects in six patients. After three months, bone growth was observed and the anatomy
and function of the defect was restored without any adverse effects [72]. In another study,
human adipose tissue-derived MSCs in combination with platelet-rich plasma, hyaluronic
acid, and CaCl2 were injected into the knees of osteoarthritis patients. Bone and cartilage
regeneration were observed over three months and showed increased cartilage volume and
bone regeneration [67]. Histological assessment confirmed the formation of hyaline-like
cartilage integrated into subchondral bone. Poor integration of cartilage into bone is one of
the most common problems in articular cartilage repair [67,73]. Furthermore, the efficiency
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and safety of an intra-articular injection of adipose tissue-derived MSCs in osteoarthritis
patients was also investigated [67].
In summary, these studies in the literature not only support the use of IPFP-derived
MSC for osteoarthritis therapy and articular cartilage regeneration, but they also provide
encouraging clinical results. There are, however, some limitations to the use of IPFP-derived
MSC in clinical applications; in human models, researchers typically obtain IPFP tissues
from patients that have been diagnosed with osteoarthritis, which affects the function and
differentiation activity of IPFP-derived MSC [63,64].
MSCs have shown promise in regenerative medicine and tissue engineering. In the
field of regenerative medicine, cell therapy methods involving direct injection, cell seeding
on scaffolds, and transplantation of stem cells to the site of the defect have been applied [67].
Much of the evidence in this review supports the use of MSCs together with scaffolds
comprising a proper biomimetic structure [74].
Before using MSCs, it is necessary to choose the specific tissue and MSCs for more
efficient cartilage regeneration [75]. Identifying the anatomical location of the tissue to
harvest MSCs from and the characterization methods to use for the MSCs are promising
future directions for this field [76]. Adipose-derived MSCs that are used in cell therapy are
obtained mostly from subcutaneous adipose tissue by liposuction. Previous studies have
demonstrated that the mechanical disruption associated with liposuction may adversely
affect MSCs and may reduce their proliferative capacity [51,77,78]. The IPFP is a rich source
of MSCs for articular cartilage regeneration and contains a high number of chondropro-
genitor cells [45,72]. Evidence suggests that the IPFP location [79] adjacent to the synovial
membrane and fluid potentiates its use for articular cartilage regeneration [80–82]. The
literature suggests that the proliferation and differentiation potential of IPFP-derived MSCs
is independent of age, while MSCs from other sources generally undergo an age-related de-
cline in potential [66]. Recently, IPFP-derived MSCs have been used in cell-based therapies
for healing cartilage defects, as reported by Ashton et al. [83].
The self-repair capacity of hyaline cartilage is very limited. Although small subchon-
dral defects may spontaneously repair with the production of hyaline cartilage, larger
chondral defects generally heal with fibrocartilage [39]. Fibrocartilage is histochemically
and biomechanically inferior to normal hyaline cartilage. Cartilage defects frequently
progress to more generalized osteoarthritic changes [84]. Interestingly, a study has shown
that hyaline cartilage may not be the definitive repair tissue in the healing of articular
cartilage defects [85], and it may be produced at an intermediary stage; in the process of
ossification, hyaline cartilage is formed first. So, detailed studies are necessary for articular
cartilage repair. In addition, the use of suitable harvesting methods would improve the
efficacy of IPFP-derived MSCs in their future therapeutic role in regenerative medicine [86].
Wei et al. reported that the immunohistochemical analysis of IPFP and adipose tissue indi-
cated that IPFP contains more macrophages [65] (Figure 1). Previous studies have shown
that pro-inflammatory macrophages prevent chondrogenesis and induce MSCs to produce
a fibrocartilage matrix [87,88]. Therefore, due to the various challenges and opinions
regarding the therapeutic role of IPFP-derived MSCs, further studies are needed [21].
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Figure 1. IPFP inhibits chondrogenic differentiation of MSCs. Immunohistochemically stained images of pellets from MSC 
donors for glycosaminoglycans with thionin or collagen type II and collagen type I showing IPFP decreased thionin and 
collagen type II, whereas collagen type I Scheme 65. Copyright 2015, Elsevier. 
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Figure 1. IPFP inhibits chondrogenic differentiation of MSCs. Immunohistochemically stained images of pellets from
MSC donors for glycosaminoglycans with thionin or collagen type II and collagen type I showing IPFP decreased thionin
and collagen type II, whereas collagen type I staining was not affected. Reproduced with permission [65]. Copyright
2015, Elsevier.
5. Conclusions
In summary, the use of IPFP-derived MSCs to regenerate articular cartilage has
achieved better results than MSCs from other sources. The collaboration of researchers
from many disciplines and different fields will help solve current challenges facing the ther-
apeutic applications of IPFP-derived MSCs and may create new therapies for the treatment
of articular cartilage defects.
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